The state health plan currently has a $507 million deficit. Pharmacy benefit managers, the intermediaries in the drug supply chain, are supposed to use their bargaining power to negotiate lower drug ...

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

A study has suggested that the use of weight-loss jabs may be associated with wider health benefits, including a lower risk ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.